Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Expression Pathology Provides Roche its Liquid Tissue®-SRM Protein Biomarker Assay Services in Drug Development

Published: Wednesday, January 12, 2011
Last Updated: Wednesday, January 12, 2011
Bookmark and Share
The Liquid Tissue®-SRM Technology accelerates identification of cancer molecular markers for developing more effective treatments.

Expression Pathology Inc. has announced an agreement with Roche wherein Expression Pathology will provide its Liquid Tissue®-SRM Technology to accelerate identification of cancer molecular markers for developing more effective treatments.

Under the terms of the agreement, Expression Pathology will support Roche oncology drug development programs with multiplexed quantitative assays of cancer signaling pathway proteins and their activation in FFPE tissues by mass spectrometry.

“This new approach to tissue analysis has the potential to dramatically stream-line and improve biomarker identification in FFPE samples during clinical development,” says Dr. Miro Venturi, Senior Biomarker & Experimental Medicine Leader at Roche. “Longer-term, we may envision Expression Pathology’s Liquid Tissue®-SRM platform as becoming a new way of profiling tumors at the molecular level to improve patient stratification and therefore advancing our discovery of personalized medicines.”

“This collaboration with Roche is a key step towards developing valuable clinical assays to improve patient treatment decisions for Roche’s innovative new targeted therapies.” says Casey Eitner, President and CEO of Expression Pathology.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Expression Pathology Obtains Second U.S. Liquid Tissue® Patent
Patent cover methods that increase the range of proteins and protein modifications which can be analyzed using the company’s patented Liquid Tissue® method.
Sunday, April 10, 2011
Expression Pathology provides Roche its Liquid Tissue®-SRM Protein Biomarker Assay Services in Drug Development
Expression Pathology Inc. announced an agreement with Roche wherein Expression Pathology will provide its Liquid Tissue®-SRM Technology to accelerate identification of cancer molecular markers for developing more effective treatments.
Tuesday, January 11, 2011
Flagship Partners with Expression Pathology to Combine Tissue Proteomics and Digital Pathology
Two leading companies offer clients integrated services for digital pathology and quantitative mass-spec based tissue proteomics.
Sunday, December 12, 2010
Expression Pathology’s Liquid Tissue Patent Issues in Japan
Patent covers tissue processing methods to enable discovery and accurate measurement of protein biomarkers in standard FFPE tissue by mass spectrometry.
Tuesday, September 28, 2010
Key U.S. Patent Issues on Expression Pathology’s Liquid Tissue® Technology
The patent claims methods to enable protein analysis in FFPE tissue for clinical research and diagnostics.
Wednesday, January 07, 2009
Expression Pathology to Collaborate in $300,000 Alberta Breast Cancer Research
EPI will employ its tissue proteomics technologies to identify protein biomarkers of metastasis.
Tuesday, September 30, 2008
EPI Licenses Harvard’s AQUA™ Peptide Technology
Company licenses the patent rights for mass spectrometry quantitation of proteins in patient tissue.
Wednesday, August 30, 2006
Publication Shows Cancer Biomarker Identification in Formalin-Fixed Tissue
The article describes LC MS/MS mass spectrometry analysis of FFPE prostate cancer tissue.
Thursday, November 10, 2005
Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Rapid Retrieval of Live, Infectious Pathogens from Clinical Samples
An engineered pathogen-binding protein enables rapid isolation of infectious bacteria from joint fluids and accelerates their identification.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Detecting Fake Parmesan Cheeses
Scientists report on a way to catch adulteration of the regional artisanal products.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Process Analysis in Real Time
With a real-time mass spectrometer developed by Fraunhofer researchers, it has become possible for the first time to analyze up to 30 components simultaneously from the gas phase and a liquid, including in-situ analysis.
Triple-Negative Breast Cancer Target Is Found
Researchers at UC Berkeley discover a target that drives cancer metabolism in triple-negative breast cancer.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!